BLU News and Press, BELLUS Health Inc. From 09/13/21

Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...

Interim analysis met the threshold for a high probability of clinical efficacy Data from interim analysis support accelerated planning for the Phase 3 program SOOTHE Phase 2b trial is on track to deliver topline results in Q4 2021 BELLUS Health Inc. (Nasdaq:B...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...

These Penny Stocks May Turn Heads Next Month A great thing about penny stocks and the market, in general, is that there isn’t one right or wrong way to research. Where some traders look at fundamentals and corporate growth, others seek out technical trends and market momentum...

Bellus’ lead drug candidate, BLU-5937, has the potential to capture significant market share if the drug attains commercialization. Bellus has adequate cash on its books, lasting until at least the duration of 2022. The company has no long-term debt. Bellus claims 100% owne...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...

- The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 - BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developin...

The TSX continues to outperform in July 2021 amid the threats of emerging COVID variants. Bargain stocks are plenty, too, if you’re on the hunt for great deals. Stocks like Canacol Energy (TSX:CNE) , Fire & Flower (TSX:FAF) , and Bellus Health (TSX:BLU) ...

Canadians looking for growth stocks to buy will find three great choices in the healthcare sector. The share prices range from less than a dollar to not more than $8. Also, market analysts forecast a return potential of between 61% to 136%. Take positions today before the stocks take of...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...